Compare Biocon with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ALEMBIC PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ALEMBIC PHARMA BIOCON /
ALEMBIC PHARMA
 
P/E (TTM) x 31.2 16.6 187.7% View Chart
P/BV x 3.7 6.6 56.3% View Chart
Dividend Yield % 0.3 0.6 45.9%  

Financials

 BIOCON    ALEMBIC PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
ALEMBIC PHARMA
Mar-19
BIOCON /
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs707664 106.5%   
Low Rs554412 134.3%   
Sales per share (Unadj.) Rs91.9208.7 44.0%  
Earnings per share (Unadj.) Rs16.731.0 53.9%  
Cash flow per share (Unadj.) Rs24.237.1 65.1%  
Dividends per share (Unadj.) Rs1.005.50 18.2%  
Dividend yield (eoy) %0.21.0 15.5%  
Book value per share (Unadj.) Rs101.6144.2 70.5%  
Shares outstanding (eoy) m600.00188.52 318.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.6 266.1%   
Avg P/E ratio x37.717.4 217.3%  
P/CF ratio (eoy) x26.114.5 179.9%  
Price / Book Value ratio x6.23.7 166.3%  
Dividend payout %6.017.7 33.7%   
Avg Mkt Cap Rs m378,330101,461 372.9%   
No. of employees `0006.1NA-   
Total wages/salary Rs m11,6537,467 156.1%   
Avg. sales/employee Rs Th8,994.3NM-  
Avg. wages/employee Rs Th1,900.7NM-  
Avg. net profit/employee Rs Th1,635.3NM-  
INCOME DATA
Net Sales Rs m55,14439,347 140.1%  
Other income Rs m1,44494 1,539.4%   
Total revenues Rs m56,58839,441 143.5%   
Gross profit Rs m15,8838,736 181.8%  
Depreciation Rs m4,4781,152 388.6%   
Interest Rs m709184 385.1%   
Profit before tax Rs m12,1407,493 162.0%   
Minority Interest Rs m911 83.3%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1231,568 135.4%   
Profit after tax Rs m10,0265,844 171.6%  
Gross profit margin %28.822.2 129.7%  
Effective tax rate %17.520.9 83.6%   
Net profit margin %18.214.9 122.4%  
BALANCE SHEET DATA
Current assets Rs m48,22819,577 246.3%   
Current liabilities Rs m30,37614,896 203.9%   
Net working cap to sales %32.411.9 272.1%  
Current ratio x1.61.3 120.8%  
Inventory Days Days6890 76.1%  
Debtors Days Days8645 188.5%  
Net fixed assets Rs m64,13027,097 236.7%   
Share capital Rs m3,000377 795.8%   
"Free" reserves Rs m57,98026,811 216.3%   
Net worth Rs m60,98027,188 224.3%   
Long term debt Rs m15,7664,993 315.8%   
Total assets Rs m121,92447,778 255.2%  
Interest coverage x18.141.7 43.5%   
Debt to equity ratio x0.30.2 140.8%  
Sales to assets ratio x0.50.8 54.9%   
Return on assets %8.812.6 69.8%  
Return on equity %16.421.5 76.5%  
Return on capital %16.823.6 71.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50619,453 79.7%   
Fx outflow Rs m10,3996,065 171.5%   
Net fx Rs m5,10713,388 38.1%   
CASH FLOW
From Operations Rs m11,5468,120 142.2%  
From Investments Rs m-7,138-7,556 94.5%  
From Financial Activity Rs m-2,417590 -409.4%  
Net Cashflow Rs m2,1031,153 182.3%  

Share Holding

Indian Promoters % 40.4 74.1 54.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.9 289.7%  
FIIs % 10.7 9.1 117.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 13.9 143.2%  
Shareholders   109,995 49,328 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ORCHID PHARMA  WYETH  ABBOTT INDIA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 27, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS